The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...

New Treatments for HR-Positive Breast Cancer and Mantle Cell Lymphoma Offer Promising Outcomes and Expanded Options for ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...

India’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a kind of blood cancer that affects ...

Researchers at Karolinska Institutet and the Astrid Lindgren Children's Hospital in Sweden have determined how children's ...

Sachin Jain, an analyst from Bank of America Securities, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price ...

The heavily traveled northeastern portion of the Interstate 95 corridor is expected to experience a significant bout of snow as a winter storm strengthens along the coastline.

Their new life is finally starting to slow down. "Life just happens really fast and we wanted to do something else before it was too late, physically and also mentally," Sabine, 51, told BI.

Immunotherapeutic interventions are showing promise in cancer treatment, but challenges like low response rates, off-target delivery, and toxicity still ...